- Home
- LBRX vs ORGO Comparison
LBRX vs ORGO Comparison
Compare LBRX & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LBRX | ORGO |
|---|---|---|
| Founded | 2015 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 602.6M | 514.0M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | LBRX | ORGO |
|---|---|---|
| Price | $23.91 | $2.70 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 3 |
| Target Price | ★ $49.00 | $7.67 |
| AVG Volume (30 Days) | 181.2K | ★ 670.4K |
| Earning Date | 01-01-0001 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1600.00 |
| EPS | N/A | ★ 0.15 |
| Revenue | N/A | ★ $564,169,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $17.84 |
| P/E Ratio | ★ N/A | $18.50 |
| Revenue Growth | N/A | ★ 17.04 |
| 52 Week Low | $13.40 | $2.61 |
| 52 Week High | $25.60 | $7.08 |
Technical Indicators
Market Signals| Indicator | LBRX | ORGO |
|---|---|---|
| Relative Strength Index (RSI) | 52.85 | 23.23 |
| Support Level | $22.34 | $2.61 |
| Resistance Level | $24.70 | $5.08 |
| Average True Range (ATR) | 1.26 | 0.23 |
| MACD | -0.14 | -0.09 |
| Stochastic Oscillator | 51.76 | 3.95 |
Price Performance
Historical ComparisonAbout LBRX LB Pharmaceuticals Inc
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.
About ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.